Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of
 patients with knee osteoarthritis (OA)
Inclusion Criteria:

 -  Primary osteoarthritis of knee (confirmed by American College of Rheumatology [ACR]
 criteria).

 -  Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.

 Exclusion Criteria:

 -  Evidence of active peptic ulceration within 12 months prior to the screening visit or
 history of active gastrointestinal bleeding within the previous 5 years.

 -  Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).

 Other protocol-defined inclusion/exclusion criteria may apply